首页 > 最新文献

Infectious Diseases in Clinical Practice最新文献

英文 中文
Rapid Diagnosis of Bartonella-Induced Hemophagocytic Lymphohistiocytosis Using Next-Generation Sequencing of Plasma 利用下一代血浆测序快速诊断巴尔通体诱导的噬血细胞淋巴组织细胞病
Q4 Medicine Pub Date : 2023-10-06 DOI: 10.1097/ipc.0000000000001301
Kristin E. Mondy, Rama Thyagarajan, H. Stephen Han, Brian Lee
Abstract Hemophagocytic lymphohistiocytosis (HLH) is characterized by uncontrolled activation of macrophages and phagocytosis of hematopoietic cells. Recognition and treatment are often delayed in infectious triggers of HLH because of lack of rapid and reliable diagnostic modalities, as well as the need for invasive tissue sampling. We report a rare case of Bartonella -induced HLH in a kidney transplant patient who presented with fever of unknown origin. The diagnosis was expedited with next-generation sequencing of microbial cell-free DNA. We also describe the successful treatment outcome with antibiotics alone and the promising utility of this newer diagnostic method.
噬血细胞淋巴组织细胞病(Hemophagocytic lymphohitiocytosis, HLH)的特点是巨噬细胞不受控制的活化和造血细胞的吞噬。由于缺乏快速可靠的诊断方式,以及需要侵入性组织采样,对HLH的感染性触发因素的识别和治疗往往被延迟。我们报告一个罕见的病例巴尔通体诱导的HLH在肾移植病人谁提出发烧不明来源。新一代微生物无细胞DNA测序加快了诊断。我们还描述了单独使用抗生素的成功治疗结果和这种较新的诊断方法的有前途的效用。
{"title":"Rapid Diagnosis of Bartonella-Induced Hemophagocytic Lymphohistiocytosis Using Next-Generation Sequencing of Plasma","authors":"Kristin E. Mondy, Rama Thyagarajan, H. Stephen Han, Brian Lee","doi":"10.1097/ipc.0000000000001301","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001301","url":null,"abstract":"Abstract Hemophagocytic lymphohistiocytosis (HLH) is characterized by uncontrolled activation of macrophages and phagocytosis of hematopoietic cells. Recognition and treatment are often delayed in infectious triggers of HLH because of lack of rapid and reliable diagnostic modalities, as well as the need for invasive tissue sampling. We report a rare case of Bartonella -induced HLH in a kidney transplant patient who presented with fever of unknown origin. The diagnosis was expedited with next-generation sequencing of microbial cell-free DNA. We also describe the successful treatment outcome with antibiotics alone and the promising utility of this newer diagnostic method.","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134945452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 20-Day Course of Nirmatrelvir/r in a Young Man Newly Diagnosed With Acquired Immunodeficiency Syndrome Carrying Persistent Omicron BA.2 Infection 一名新诊断为获得性免疫缺陷综合征并携带持续性组粒BA.2感染的年轻男性接受尼马特利韦/r治疗20天
Q4 Medicine Pub Date : 2023-10-06 DOI: 10.1097/ipc.0000000000001291
Giuseppe Bruno, Claudia Fabrizio, Marilina Tampoia, Maria Chironna, Giovanni Battista Buccoliero
Bruno, Giuseppe MD; Fabrizio, Claudia MD; Tampoia, Marilina MD; Chironna, Maria PhD; Buccoliero, Giovanni Battista MD Author Information
布鲁诺,朱塞佩医学博士;法布里齐奥,克劳迪娅医学博士;坦波亚,玛丽莉娜医学博士;奇隆纳,玛丽亚医学博士;布科利埃罗,乔瓦尼-巴蒂斯塔医学博士 作者信息
{"title":"A 20-Day Course of Nirmatrelvir/r in a Young Man Newly Diagnosed With Acquired Immunodeficiency Syndrome Carrying Persistent Omicron BA.2 Infection","authors":"Giuseppe Bruno, Claudia Fabrizio, Marilina Tampoia, Maria Chironna, Giovanni Battista Buccoliero","doi":"10.1097/ipc.0000000000001291","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001291","url":null,"abstract":"Bruno, Giuseppe MD; Fabrizio, Claudia MD; Tampoia, Marilina MD; Chironna, Maria PhD; Buccoliero, Giovanni Battista MD Author Information","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134945315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Methylprednisolone Pulse on the Mortality of Patients With Acute Respiratory Distress Syndrome Secondary to COVID-19 甲基强的松龙脉冲治疗对COVID-19继发急性呼吸窘迫综合征患者死亡率的影响
Q4 Medicine Pub Date : 2023-09-25 DOI: 10.1097/ipc.0000000000001296
Adrián Sousa, Olalla Lima, Alexandre Pérez-González, Alejandro Araujo, Rebeca Longueira, Antón Otero, Marta Núñez, Cristina Ramos, Lucía Martínez-Lamas, Manuel Crespo-Casal, Martin Rubianes, María Teresa Pérez-Rodríguez
Introduction Corticosteroids have been thoroughly used in the treatment of COVID-19. The aim of the study was to analyze the impact of methylprednisolone pulse on in-hospital mortality of patients with acute respiratory distress syndrome (ARDS) due to COVID-19. Methods We conducted a retrospective, single-center observational study. We selected adult patients admitted to the hospital with the diagnosis of COVID-19 between March and June 2020. Cox regression was used to identify the factors associated with in-hospital mortality. Results A total of 306 patients were analyzed. In-hospital crude mortality rate was 17%. Diabetes mellitus (hazard ratio [HR], 5.5; 95% confidence interval [CI], 1.40–4.55), dementia (HR, 7.7; 95% CI, 4.25–13.87) and ARDS (HR, 4.2; 95% CI, 2.34–7.46) were associated with in-hospital mortality. In patients with ARDS diagnosis, the only in-hospital mortality risk factor was dementia (HR, 5.2; 95% CI, 2.44–11.07), whereas methylprednisolone pulse was a protective factor (HR, 0.2; 95% CI, 0.09–0.63). In the follow-up, 40% of patients had some symptom related to COVID-19. Conclusions Methylprednisolone pulse reduced the in-hospital mortality in patients with ARDS due to COVID-19. A high percentage of patients presented persistent symptoms in 90 days after the hospital discharge.
糖皮质激素已被广泛应用于COVID-19的治疗。本研究的目的是分析甲基强的松龙脉冲对COVID-19急性呼吸窘迫综合征(ARDS)患者住院死亡率的影响。方法采用回顾性、单中心观察性研究。我们选择了2020年3月至6月期间入院诊断为COVID-19的成年患者。采用Cox回归分析确定与住院死亡率相关的因素。结果共分析306例患者。院内粗死亡率为17%。糖尿病(危险比[HR], 5.5;95%可信区间[CI], 1.40-4.55),痴呆(相对危险度,7.7;95% CI, 4.25-13.87)和ARDS (HR, 4.2;95% CI, 2.34-7.46)与住院死亡率相关。在诊断为ARDS的患者中,唯一的院内死亡危险因素是痴呆(HR, 5.2;95% CI, 2.44-11.07),而甲基强的松龙脉冲是保护因素(HR, 0.2;95% ci, 0.09-0.63)。在随访中,40%的患者出现了与COVID-19相关的症状。结论甲强的松龙脉冲治疗可降低COVID-19急性呼吸窘迫综合征患者的住院死亡率。患者出院后90天出现持续症状的比例很高。
{"title":"Impact of Methylprednisolone Pulse on the Mortality of Patients With Acute Respiratory Distress Syndrome Secondary to COVID-19","authors":"Adrián Sousa, Olalla Lima, Alexandre Pérez-González, Alejandro Araujo, Rebeca Longueira, Antón Otero, Marta Núñez, Cristina Ramos, Lucía Martínez-Lamas, Manuel Crespo-Casal, Martin Rubianes, María Teresa Pérez-Rodríguez","doi":"10.1097/ipc.0000000000001296","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001296","url":null,"abstract":"Introduction Corticosteroids have been thoroughly used in the treatment of COVID-19. The aim of the study was to analyze the impact of methylprednisolone pulse on in-hospital mortality of patients with acute respiratory distress syndrome (ARDS) due to COVID-19. Methods We conducted a retrospective, single-center observational study. We selected adult patients admitted to the hospital with the diagnosis of COVID-19 between March and June 2020. Cox regression was used to identify the factors associated with in-hospital mortality. Results A total of 306 patients were analyzed. In-hospital crude mortality rate was 17%. Diabetes mellitus (hazard ratio [HR], 5.5; 95% confidence interval [CI], 1.40–4.55), dementia (HR, 7.7; 95% CI, 4.25–13.87) and ARDS (HR, 4.2; 95% CI, 2.34–7.46) were associated with in-hospital mortality. In patients with ARDS diagnosis, the only in-hospital mortality risk factor was dementia (HR, 5.2; 95% CI, 2.44–11.07), whereas methylprednisolone pulse was a protective factor (HR, 0.2; 95% CI, 0.09–0.63). In the follow-up, 40% of patients had some symptom related to COVID-19. Conclusions Methylprednisolone pulse reduced the in-hospital mortality in patients with ARDS due to COVID-19. A high percentage of patients presented persistent symptoms in 90 days after the hospital discharge.","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135815491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Whipple Disease in 2 Southwest Missouri Patients 密苏里州西南部2例惠普尔病患者
Q4 Medicine Pub Date : 2023-09-25 DOI: 10.1097/ipc.0000000000001294
Nicole Hitchcock, Robin Trotman
Abstract Whipple disease (WD) is a rare condition caused by infection with Tropheryma whipplei , a ubiquitous bacterium whose detailed pathogenesis has yet to be elucidated. Its vague defining symptoms of polyarthralgia, weight loss, diarrhea, and abdominal pain do not lend themselves to a rapid diagnosis. The importance of considering WD in a differential diagnosis and recognizing the many manifestations of the condition must not be underestimated. Inadequate or delayed diagnosis can have a significant impact on morbidity and mortality. In this report, we describe 2 cases of classic WD, including representative imaging and histopathology, that were diagnosed almost simultaneously in 2 unrelated adult residents of Southwest Missouri.
摘要惠普尔病(Whipple disease, WD)是一种罕见的由惠普尔Tropheryma whipplei感染引起的疾病,惠普尔Tropheryma whipplei是一种普遍存在的细菌,其详细的发病机制尚未阐明。其模糊的多关节痛、体重减轻、腹泻和腹痛的症状不适合快速诊断。在鉴别诊断中考虑WD的重要性和认识到该病的许多表现绝不能被低估。诊断不充分或延误可对发病率和死亡率产生重大影响。在本报告中,我们描述了2例典型WD,包括代表性的影像学和组织病理学,这2例WD几乎同时被诊断为西南密苏里州的2名无血缘关系的成年居民。
{"title":"Whipple Disease in 2 Southwest Missouri Patients","authors":"Nicole Hitchcock, Robin Trotman","doi":"10.1097/ipc.0000000000001294","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001294","url":null,"abstract":"Abstract Whipple disease (WD) is a rare condition caused by infection with Tropheryma whipplei , a ubiquitous bacterium whose detailed pathogenesis has yet to be elucidated. Its vague defining symptoms of polyarthralgia, weight loss, diarrhea, and abdominal pain do not lend themselves to a rapid diagnosis. The importance of considering WD in a differential diagnosis and recognizing the many manifestations of the condition must not be underestimated. Inadequate or delayed diagnosis can have a significant impact on morbidity and mortality. In this report, we describe 2 cases of classic WD, including representative imaging and histopathology, that were diagnosed almost simultaneously in 2 unrelated adult residents of Southwest Missouri.","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135858996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telemedicine, eHealth, and Telehealth Assistance for Patients With Immunodeficiency in the Waves of COVID-19 With New Variants of the Virus 远程医疗、电子医疗和远程医疗援助在COVID-19病毒新变体的浪潮中免疫缺陷患者
Q4 Medicine Pub Date : 2023-09-25 DOI: 10.1097/ipc.0000000000001292
Mohammed Ahmed Hamad, Zahra Taati Moghadam, Majid Taati Moghadam
Hamad, Mohammed Ahmed PharmD; Moghadam, Zahra Taati BSc; Moghadam, Majid Taati PhD Author Information
Hamad, Mohammed Ahmed PharmD; Moghadam, Zahra Taati BSc; Moghadam, Majid Taati PhD 作者信息
{"title":"Telemedicine, eHealth, and Telehealth Assistance for Patients With Immunodeficiency in the Waves of COVID-19 With New Variants of the Virus","authors":"Mohammed Ahmed Hamad, Zahra Taati Moghadam, Majid Taati Moghadam","doi":"10.1097/ipc.0000000000001292","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001292","url":null,"abstract":"Hamad, Mohammed Ahmed PharmD; Moghadam, Zahra Taati BSc; Moghadam, Majid Taati PhD Author Information","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135815499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiretroviral Regimen and Pregnancy Outcomes of Women Living With Human Immunodeficiency Virus in a US Cohort 抗逆转录病毒治疗方案和美国人类免疫缺陷病毒感染者的妊娠结局
Q4 Medicine Pub Date : 2023-09-25 DOI: 10.1097/ipc.0000000000001308
Charles M. Kopp, Nasim C. Sobhani, Barbara Baker, Kenneth Tapia, Rupali Jain, Jane Hitti, Alison C. Roxby
Abstract Women who are pregnant and living with human immunodeficiency virus (HIV) have traditionally been excluded from clinical trials regarding new pharmacotherapy. Immediate initiation of antiretroviral therapy is recommended for women who are pregnant and living with HIV. Integrase strand inhibitors (INSTIs) are first-line recommended agents because they lead to more rapid HIV viral load reduction. We conducted a retrospective study of women who are pregnant and living with HIV who received prenatal care at the University of Washington. Mothers were categorized by antiretroviral therapy class: INSTI, protease inhibitors, and nonnucleoside reverse transcriptase inhibitors. χ 2 and t tests were used for the analysis of baseline characteristics, and generalized estimating equations were used to adjust for HIV viral suppression between groups. There were a total of 234 mother-infant pairs whose pregnancies progressed beyond 20 weeks. The study demonstrated that women on INSTI regimens were more likely to have a shorter time to viral load suppression than women on nonnucleoside reverse transcriptase inhibitor regimens. In addition, 7 congenital anomalies were identified in this cohort, none of which were neural tube defects. There was no perinatal transmission of HIV to any of the infants. This small cohort of women provides high-quality data regarding the safety and efficacy of INSTI use for both mothers and infants in resource-rich settings.
传统上,携带人类免疫缺陷病毒(HIV)的孕妇被排除在新药物治疗的临床试验之外。建议孕妇和感染艾滋病毒的妇女立即开始抗逆转录病毒治疗。整合酶链抑制剂(insis)是一线推荐药物,因为它们可以更快地降低HIV病毒载量。我们对在华盛顿大学接受产前护理的孕妇和感染艾滋病毒的妇女进行了回顾性研究。母亲按抗逆转录病毒治疗类别进行分类:INSTI,蛋白酶抑制剂和非核苷逆转录酶抑制剂。使用χ 2和t检验分析基线特征,并使用广义估计方程调整组间HIV病毒抑制。总共有234对怀孕超过20周的母婴。该研究表明,与使用非核苷类逆转录酶抑制剂的女性相比,使用INSTI方案的女性更有可能在更短的时间内抑制病毒载量。此外,本队列中还发现了7例先天性异常,其中没有一例为神经管缺陷。没有围生期艾滋病毒传染给任何婴儿。这一小型妇女队列提供了关于资源丰富环境中母亲和婴儿使用INSTI的安全性和有效性的高质量数据。
{"title":"Antiretroviral Regimen and Pregnancy Outcomes of Women Living With Human Immunodeficiency Virus in a US Cohort","authors":"Charles M. Kopp, Nasim C. Sobhani, Barbara Baker, Kenneth Tapia, Rupali Jain, Jane Hitti, Alison C. Roxby","doi":"10.1097/ipc.0000000000001308","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001308","url":null,"abstract":"Abstract Women who are pregnant and living with human immunodeficiency virus (HIV) have traditionally been excluded from clinical trials regarding new pharmacotherapy. Immediate initiation of antiretroviral therapy is recommended for women who are pregnant and living with HIV. Integrase strand inhibitors (INSTIs) are first-line recommended agents because they lead to more rapid HIV viral load reduction. We conducted a retrospective study of women who are pregnant and living with HIV who received prenatal care at the University of Washington. Mothers were categorized by antiretroviral therapy class: INSTI, protease inhibitors, and nonnucleoside reverse transcriptase inhibitors. χ 2 and t tests were used for the analysis of baseline characteristics, and generalized estimating equations were used to adjust for HIV viral suppression between groups. There were a total of 234 mother-infant pairs whose pregnancies progressed beyond 20 weeks. The study demonstrated that women on INSTI regimens were more likely to have a shorter time to viral load suppression than women on nonnucleoside reverse transcriptase inhibitor regimens. In addition, 7 congenital anomalies were identified in this cohort, none of which were neural tube defects. There was no perinatal transmission of HIV to any of the infants. This small cohort of women provides high-quality data regarding the safety and efficacy of INSTI use for both mothers and infants in resource-rich settings.","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135770029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe Disease Prevention Strategies of the Fukui Model Associated With Conventional and Alpha Variants of Severe Acute Respiratory Syndrome Coronavirus 2 与严重急性呼吸综合征冠状病毒常规变异和α变异相关的Fukui模型的严重疾病预防策略
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ipc.0000000000001311
Kritika Srinivasan Rajsri, Mana Rao
From the ∗Department of Molecular Pathobiology, New York University College of Dentistry †Department of Pathology, New York University School of Medicine, New York ‡Essen Medical Associates, Bronx §ArchCare, New York, NY. Correspondence to: Mana Rao, MD, ArchCare, 205 Lexington Ave, 3rd Floor, New York, NY 10016. E-mail: [email protected]. The authors have no funding or conflicts of interest to disclose.
来自纽约大学牙科学院*分子病理生物学系†纽约大学医学院病理学系Essen Medical Associates, Bronx§ArchCare, New York, NY。收信人:manarao, MD, ArchCare, 205 Lexington Ave, 3楼,New York, NY 10016。电子邮件:[email protected]。作者没有资金或利益冲突需要披露。
{"title":"Severe Disease Prevention Strategies of the Fukui Model Associated With Conventional and Alpha Variants of Severe Acute Respiratory Syndrome Coronavirus 2","authors":"Kritika Srinivasan Rajsri, Mana Rao","doi":"10.1097/ipc.0000000000001311","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001311","url":null,"abstract":"From the ∗Department of Molecular Pathobiology, New York University College of Dentistry †Department of Pathology, New York University School of Medicine, New York ‡Essen Medical Associates, Bronx §ArchCare, New York, NY. Correspondence to: Mana Rao, MD, ArchCare, 205 Lexington Ave, 3rd Floor, New York, NY 10016. E-mail: [email protected]. The authors have no funding or conflicts of interest to disclose.","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135248885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-Hospital Receipt of Ivermectin Is Associated With No Benefit in Mortality, Disease Progression, or Length of Stay for Patients With Mild to Moderate COVID-19 对于轻至中度COVID-19患者,住院接受伊维菌素与死亡率、疾病进展或住院时间无益处相关
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ipc.0000000000001285
Adam Hasse, Kimberly Korwek, Russell E. Poland
Background Use of the antiparasitic agent ivermectin as a potential treatment for early coronavirus disease 2019 (COVID-19) is not recommended, yet inpatient administration continues to be seen. Methods This was a retrospective analysis of more than 100,000 patients admitted to a large health system of community hospitals for COVID-19 to assess the association of ivermectin administration, either early in disease course or at higher severity, with mortality and disease progression (intensive care unit admission or use of mechanical ventilation). Propensity match analysis was used to account for covariates. Results Of the 122,002 patients hospitalized with COVID-19 included in this analysis, 1.1% (1380) received ivermectin while at mild to moderate severity (on room air or nasal cannula), and 0.2% (n = 293) received the drug while severe (noninvasive or mechanical ventilation). Among those who received it with mild to moderate severity, there was no effect on relative risk (RR) of mortality (RR, 1.01; 95% confidence interval [CI], 0.802–1.27), intensive care unit admission (RR, 0.984; 95% CI, 0.865–1.12), or use of mechanical ventilation (RR, 0.976; 95% CI, 0.777–1.23), but an increase in average length of stay (mean days, 8.0 vs 7.5; P < 0.001). Of those who received their first dose of ivermectin with more severe COVID-19, there was an increase in the RR of mortality (RR, 1.63; 95% CI, 1.34–1.99; P < 0.001). Conclusion Among hospitalized patients admitted with mild to moderate COVID-19, in-hospital administration of ivermectin provides no benefit in mortality or disease progression when administered early in the disease course, and may contribute to excess mortality when administered to patients at more severe disease states.
背景:不推荐使用抗寄生虫药伊维菌素作为早期冠状病毒病2019 (COVID-19)的潜在治疗方法,但仍有住院给药的情况。方法回顾性分析一个大型社区医院卫生系统收治的10万多例COVID-19患者,评估伊维菌素给药(病程早期或较高严重程度)与死亡率和疾病进展(重症监护病房入住或使用机械通气)的关系。倾向匹配分析用于解释协变量。结果纳入本分析的122,002例COVID-19住院患者中,1.1%(1380例)在轻中度严重(室内空气或鼻插管)时接受伊维菌素治疗,0.2% (n = 293)在严重(无创或机械通气)时接受伊维菌素治疗。在接受轻度至中度严重程度治疗的患者中,对死亡率的相对风险(RR)没有影响(RR, 1.01;95%可信区间[CI], 0.802-1.27),重症监护病房入院(RR, 0.984;95% CI, 0.865-1.12)或使用机械通气(RR, 0.976;95% CI, 0.777-1.23),但平均住院时间增加(平均天数,8.0 vs 7.5;P & lt;0.001)。在那些接受第一剂伊维菌素治疗的COVID-19更严重的患者中,死亡率的RR增加(RR, 1.63;95% ci, 1.34-1.99;P & lt;0.001)。结论在轻中度COVID-19住院患者中,在病程早期给予伊维菌素对死亡率或疾病进展没有益处,而在病情较严重的患者中给予伊维菌素可能导致死亡率过高。
{"title":"In-Hospital Receipt of Ivermectin Is Associated With No Benefit in Mortality, Disease Progression, or Length of Stay for Patients With Mild to Moderate COVID-19","authors":"Adam Hasse, Kimberly Korwek, Russell E. Poland","doi":"10.1097/ipc.0000000000001285","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001285","url":null,"abstract":"Background Use of the antiparasitic agent ivermectin as a potential treatment for early coronavirus disease 2019 (COVID-19) is not recommended, yet inpatient administration continues to be seen. Methods This was a retrospective analysis of more than 100,000 patients admitted to a large health system of community hospitals for COVID-19 to assess the association of ivermectin administration, either early in disease course or at higher severity, with mortality and disease progression (intensive care unit admission or use of mechanical ventilation). Propensity match analysis was used to account for covariates. Results Of the 122,002 patients hospitalized with COVID-19 included in this analysis, 1.1% (1380) received ivermectin while at mild to moderate severity (on room air or nasal cannula), and 0.2% (n = 293) received the drug while severe (noninvasive or mechanical ventilation). Among those who received it with mild to moderate severity, there was no effect on relative risk (RR) of mortality (RR, 1.01; 95% confidence interval [CI], 0.802–1.27), intensive care unit admission (RR, 0.984; 95% CI, 0.865–1.12), or use of mechanical ventilation (RR, 0.976; 95% CI, 0.777–1.23), but an increase in average length of stay (mean days, 8.0 vs 7.5; P < 0.001). Of those who received their first dose of ivermectin with more severe COVID-19, there was an increase in the RR of mortality (RR, 1.63; 95% CI, 1.34–1.99; P < 0.001). Conclusion Among hospitalized patients admitted with mild to moderate COVID-19, in-hospital administration of ivermectin provides no benefit in mortality or disease progression when administered early in the disease course, and may contribute to excess mortality when administered to patients at more severe disease states.","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135248889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Facial Palsy After Multisystem Inflammatory Syndrome in Children 儿童多系统炎症综合征后面瘫
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ipc.0000000000001289
Yamini Mandelia, Katherine Moravec, Kathleen Kinney Bryant, William A.B. Dalzell
Abstract COVID-19 pandemic has affected the pediatric and adult populations in different ways. Although adults experience more respiratory disease, pediatric population has been struck by multisystem inflammatory syndrome in children. There have been multiple case reports of Bell’s palsy associated with acute COVID-19 infection. We present the first known case of unilateral facial palsy after multisystem inflammatory syndrome in children in a pediatric patient.
COVID-19大流行对儿童和成人的影响不同。虽然成人经历更多的呼吸系统疾病,但儿童多系统炎症综合征在儿童人群中受到打击。已有多例贝尔氏麻痹与急性COVID-19感染相关的病例报告。我们提出的第一例已知的单侧面瘫后,多系统炎症综合征的儿童在儿科患者。
{"title":"Facial Palsy After Multisystem Inflammatory Syndrome in Children","authors":"Yamini Mandelia, Katherine Moravec, Kathleen Kinney Bryant, William A.B. Dalzell","doi":"10.1097/ipc.0000000000001289","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001289","url":null,"abstract":"Abstract COVID-19 pandemic has affected the pediatric and adult populations in different ways. Although adults experience more respiratory disease, pediatric population has been struck by multisystem inflammatory syndrome in children. There have been multiple case reports of Bell’s palsy associated with acute COVID-19 infection. We present the first known case of unilateral facial palsy after multisystem inflammatory syndrome in children in a pediatric patient.","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135248887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carbapenem Appropriateness in a Rural Facility 农村设施中碳青霉烯的适宜性
IF 0.5 Q4 Medicine Pub Date : 2023-08-21 DOI: 10.1097/ipc.0000000000001293
J. Cole
Inappropriate carbapenem prescribing leads to increased resistance, secondary infections, serious side effects, and wasted resources. A history of penicillin allergy has been identified as a potential trigger for inappropriate carbapenem prescribing. The PEN-FAST score is a validated tool that provides a high negative predictive value for allergic reaction with low scores. The objectives of this study were to determine the proportion of imipenem/cilastatin and meropenem prescriptions deemed appropriate according to published criteria and to evaluate the proportion of penicillin allergies with a low PEN-FAST score. A convenience sample of 100 carbapenem prescriptions (imipenem/cilastatin [n = 50] and meropenem [n = 50]) was evaluated with a retrospective chart review. Objective published criteria were used to assign a score of appropriate, suboptimal, or inappropriate. In patients with a history of penicillin allergy, a PEN-FAST score was retrospectively applied. Indications for use and risk factors for resistant infections were also recorded. Analysis was largely descriptive statistics, with a χ2 used to compare drug cohorts in R Studio. Prescribing was considered appropriate (25%), suboptimal (20%), and inappropriate (55%) in the combined cohort. Inappropriate prescribing was more common with imipenem/cilastatin (66% vs. 44%, P = 0.03). In 28 patients with a historical penicillin allergy, the PEN-FAST score was 0 (low risk for reaction) in the majority of cases (93%). Inappropriate carbapenem prescribing is common at the study facility and may benefit from directed antimicrobial stewardship measures. Implementing the PEN-FAST scoring method may be beneficial in a multifaceted intervention.
不适当的碳青霉烯类药物处方会导致耐药性增加、继发感染、严重副作用和资源浪费。青霉素过敏史已被确定为不适当的碳青霉烯类药物处方的潜在诱因。PEN-FAST评分是一种经过验证的工具,可为低分过敏反应提供高阴性预测值。本研究的目的是根据已公布的标准确定亚胺培南/西司他丁和美罗培南处方的比例,并评估低PEN-FAST评分的青霉素过敏比例。对100个碳青霉烯处方(亚胺培南/西司他丁[n=50]和美罗培南[n=50])的方便样本进行了回顾性图表评估。客观公布的标准用于分配适当、次优或不适当的分数。在有青霉素过敏史的患者中,对PEN-FAST评分进行了回顾性应用。还记录了耐药感染的使用适应症和风险因素。分析主要是描述性统计,χ2用于比较R Studio中的药物队列。在联合队列中,处方被认为是合适的(25%)、次优的(20%)和不合适的(55%)。亚胺培南/西司他丁的处方不恰当更为常见(66%对44%,P=0.03)。在28名有青霉素过敏史的患者中,大多数病例(93%)的PEN-FAST评分为0(反应风险低)。不适当的碳青霉烯类药物处方在研究机构很常见,可能受益于直接的抗菌管理措施。在多方面的干预中,实施PEN-FAST评分方法可能是有益的。
{"title":"Carbapenem Appropriateness in a Rural Facility","authors":"J. Cole","doi":"10.1097/ipc.0000000000001293","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001293","url":null,"abstract":"\u0000 \u0000 Inappropriate carbapenem prescribing leads to increased resistance, secondary infections, serious side effects, and wasted resources. A history of penicillin allergy has been identified as a potential trigger for inappropriate carbapenem prescribing. The PEN-FAST score is a validated tool that provides a high negative predictive value for allergic reaction with low scores. The objectives of this study were to determine the proportion of imipenem/cilastatin and meropenem prescriptions deemed appropriate according to published criteria and to evaluate the proportion of penicillin allergies with a low PEN-FAST score.\u0000 \u0000 \u0000 \u0000 A convenience sample of 100 carbapenem prescriptions (imipenem/cilastatin [n = 50] and meropenem [n = 50]) was evaluated with a retrospective chart review. Objective published criteria were used to assign a score of appropriate, suboptimal, or inappropriate. In patients with a history of penicillin allergy, a PEN-FAST score was retrospectively applied. Indications for use and risk factors for resistant infections were also recorded. Analysis was largely descriptive statistics, with a χ2 used to compare drug cohorts in R Studio.\u0000 \u0000 \u0000 \u0000 Prescribing was considered appropriate (25%), suboptimal (20%), and inappropriate (55%) in the combined cohort. Inappropriate prescribing was more common with imipenem/cilastatin (66% vs. 44%, P = 0.03). In 28 patients with a historical penicillin allergy, the PEN-FAST score was 0 (low risk for reaction) in the majority of cases (93%).\u0000 \u0000 \u0000 \u0000 Inappropriate carbapenem prescribing is common at the study facility and may benefit from directed antimicrobial stewardship measures. Implementing the PEN-FAST scoring method may be beneficial in a multifaceted intervention.\u0000","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44310498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infectious Diseases in Clinical Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1